SG11201810656WA - Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent - Google Patents

Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent

Info

Publication number
SG11201810656WA
SG11201810656WA SG11201810656WA SG11201810656WA SG11201810656WA SG 11201810656W A SG11201810656W A SG 11201810656WA SG 11201810656W A SG11201810656W A SG 11201810656WA SG 11201810656W A SG11201810656W A SG 11201810656WA SG 11201810656W A SG11201810656W A SG 11201810656WA
Authority
SG
Singapore
Prior art keywords
international
crystalline form
novartis
pct
butanamide
Prior art date
Application number
SG11201810656WA
Inventor
Jiping Fu
Siyi Jiang
Andreas Kordikowski
Zachary Kevin Sweeney
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201810656WA publication Critical patent/SG11201810656WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 December 2017 (21.12.2017) WIP0 I PCT 0111111010 0111 inn Oil ioo monliflo oimIE (10) International Publication Number WO 2017/216705 Al (51) International Patent Classification: C07D 261/08 (2006.01) A61P 31/04 (2006.01) A61K 31/42 (2006.01) (21) International Application Number: PCT/IB2017/053468 (22) International Filing Date: 12 June 2017 (12.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/CN2016/085694 14 June 2016 (14.06.2016) CN (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH). (72) Inventors: FU, Jiping; Novartis Institutes for BioMedical Research Inc., 5300 Chiron Way, Emeryville, California 94608 (US). JIANG, Siyi; Beijing Novartis Pharma Co. Ltd., 4218 Jinke Road, Zhangjiang Hi-Tech Park, Shang- hai 201203 (CN). KORDIKOWSKI, Andreas; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). SWEENEY, Zachary Kevin; 143 King Street, Redwood City, Califor- nia 94602 (US). (74) Agent: NOVARTIS AG; Lichtstrasse 35, 4056 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: — with international search report (Art. 21(3)) (54) Title: CRYSTALLINE FORM OF (R)-4-(5-(CYCLOPROPYLETHYNYL)ISOXAZOL-3-YL)-N-HYDROXY-2-METHYL-2- (METHYLSULFONYL)BUTANAMIDE AS AN ANTIBACTERIAL AGENT O N 1-1 N_ N O 1-1 N C (A) (57) : The invention relates to a crystalline form of the (R)-4-(5- (cyclopropylethynypisoxazol-3-y1)-N-hydroxy-2-methy1-2- (methylsulfonyl)butanamide (i.e. the compound of formula (A)) with low hy- droscopicity. The compound and compositions thereof are useful to treat bac- terial infections and in particular Gram negative bacterial infections, includ- ing mult-drug resistant strains. The crystalline form is prepared by dissolving an amorphous form of the compound in a halogenated organic solvent (e.g. dichloromethane) and precipitating the crystalline form with a hydrocarbon solvent (e.g. heptane).(A)
SG11201810656WA 2016-06-14 2017-06-12 Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent SG11201810656WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016085694 2016-06-14
PCT/IB2017/053468 WO2017216705A1 (en) 2016-06-14 2017-06-12 Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent

Publications (1)

Publication Number Publication Date
SG11201810656WA true SG11201810656WA (en) 2018-12-28

Family

ID=59337734

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810656WA SG11201810656WA (en) 2016-06-14 2017-06-12 Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent

Country Status (28)

Country Link
US (1) US10071973B2 (en)
EP (1) EP3468957B1 (en)
JP (1) JP6941630B2 (en)
KR (1) KR20190018637A (en)
CN (1) CN109311828A (en)
AU (1) AU2017283768B2 (en)
BR (1) BR112018074983A2 (en)
CA (1) CA3026356A1 (en)
CL (1) CL2018003559A1 (en)
CY (1) CY1123368T1 (en)
DK (1) DK3468957T3 (en)
EA (1) EA036243B1 (en)
ES (1) ES2820502T3 (en)
HR (1) HRP20201524T1 (en)
HU (1) HUE050796T2 (en)
IL (1) IL263299A (en)
MA (1) MA45250B1 (en)
MD (1) MD3468957T2 (en)
MX (1) MX2018015634A (en)
PH (1) PH12018502523A1 (en)
PL (1) PL3468957T3 (en)
PT (1) PT3468957T (en)
SG (1) SG11201810656WA (en)
SI (1) SI3468957T1 (en)
TW (1) TWI746572B (en)
UA (1) UA123790C2 (en)
WO (1) WO2017216705A1 (en)
ZA (1) ZA201807680B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107375211B (en) * 2017-08-24 2021-02-26 正大制药（青岛）有限公司 Children sublingual spray of tosufloxacin tosylate and preparation method thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3381783D1 (en) 1982-03-03 1990-09-13 Genentech Inc HUMAN ANTITHROMBIN III, DNA SEQUENCES THEREFOR, EXPRESSION AND CLONING VECTORS CONTAINING SUCH SEQUENCES AND THEREFORE TRANSFORMED CELL CULTURES, METHOD FOR EXPRESSING HUMAN ANTITHROMBIN III AND THESE CONTAINERS.
DE59009528D1 (en) 1989-09-22 1995-09-21 Basf Ag Carboxamides.
EP1947183B1 (en) 1996-08-16 2013-07-17 Merck Sharp & Dohme Corp. Mammalian cell surface antigens; related reagents
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
JP2001520039A (en) 1997-10-21 2001-10-30 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Human tumor necrosis factor receptor-like proteins, TR11, TR11SV1 and TR11SV2
CA2319236A1 (en) 1998-02-09 1999-08-12 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
ATE376837T1 (en) 1999-07-12 2007-11-15 Genentech Inc STIMULATION OR INHIBITION OF ANGIOGENESIS AND CARDIAC VASCULARIZATION WITH TUMOR NECROSIS FACTOR LIGAND/RECEPTOR HOMOLOGUE
US7125870B2 (en) 2002-11-06 2006-10-24 Bristol-Myers Squibb Company Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
JP4511943B2 (en) 2002-12-23 2010-07-28 ワイス エルエルシー Antibody against PD-1 and use thereof
CN102267924A (en) 2003-01-08 2011-12-07 诺华疫苗和诊断公司 Antibacterial agents
CA2525717A1 (en) 2003-05-23 2004-12-09 Wyeth Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
WO2005055808A2 (en) 2003-12-02 2005-06-23 Genzyme Corporation Compositions and methods to diagnose and treat lung cancer
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
EP1866339B8 (en) 2005-03-25 2021-12-01 GITR, Inc. Gitr binding molecules and uses therefor
LT2439273T (en) 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CN105330741B (en) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
EP1981969A4 (en) 2006-01-19 2009-06-03 Genzyme Corp Gitr antibodies for the treatment of cancer
DK2170959T3 (en) 2007-06-18 2014-01-13 Merck Sharp & Dohme ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1
ES2591281T3 (en) 2007-07-12 2016-11-25 Gitr, Inc. Combination therapies that employ GITR binding molecules
BRPI0907718A2 (en) 2008-02-11 2017-06-13 Curetech Ltd method for treating a tumor, method for improving tolerability to at least one chemotherapeutic agent, method for increasing survival of an individual having a tumor, method for reducing or preventing tumor recurrence, use of a humanized monoclonal antibody or fragment and antibody thereof humanized monoclonal or fragment thereof
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
KR20110044992A (en) 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 TVF-β antagonist multi-target binding protein
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
NZ591130A (en) 2008-08-25 2012-09-28 Amplimmune Inc Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
CN102149820B (en) 2008-09-12 2014-07-23 国立大学法人三重大学 Cell capable of expressing exogenous GITR ligand
US8722686B2 (en) 2008-09-19 2014-05-13 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
SI2376535T1 (en) 2008-12-09 2017-07-31 F. Hoffmann-La Roche Ag Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5844159B2 (en) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ PD-1 antibody and PD-L1 antibody and use thereof
LT3023438T (en) 2009-09-03 2020-05-11 Merck Sharp & Dohme Corp. Anti-gitr antibodies
US8853258B2 (en) 2009-10-13 2014-10-07 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
JP2013512251A (en) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Simultaneous inhibition of PD-L1 / PD-L2
WO2011073845A1 (en) 2009-12-16 2011-06-23 Pfizer Inc. N-linked hydroxamic acid derivatives useful as antibacterial agents
SI2519543T1 (en) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Heterodimer binding proteins and uses thereof
US8877754B2 (en) 2010-09-06 2014-11-04 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
CN103298780A (en) 2010-11-10 2013-09-11 尔察祯有限公司 Hydroxamic acid derivatives and their use in the treatment of bacterial infections
UA107423C2 (en) 2011-03-07 2014-12-25 Pfizer Fluoro-pyridinone derivatives useful as antibacterial agents
DK2694488T3 (en) 2011-04-08 2014-12-15 Pfizer Isoxazole derivatives useful as antibacterial SUBSTANCES
KR20130140164A (en) 2011-04-08 2013-12-23 화이자 인코포레이티드 Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
KR101981873B1 (en) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 Anti-pd-l1 antibodies and uses thereof
AR091649A1 (en) 2012-07-02 2015-02-18 Bristol Myers Squibb Co OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
WO2014160649A1 (en) 2013-03-29 2014-10-02 Novartis Ag Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections
JPWO2015056799A1 (en) * 2013-10-18 2017-03-09 大正製薬株式会社 Hydroxamic acid derivatives
ES2687393T3 (en) * 2014-04-22 2018-10-25 Novartis Ag Isoxazoline hydroxamic acid derivatives as LpxC inhibitors
US9549916B2 (en) * 2014-12-16 2017-01-24 Novartis Ag Isoxazole hydroxamic acid compounds as LpxC inhibitors

Also Published As

Publication number Publication date
MX2018015634A (en) 2019-03-06
CY1123368T1 (en) 2021-12-31
AU2017283768A1 (en) 2018-12-06
EA201990012A1 (en) 2019-05-31
HUE050796T2 (en) 2021-01-28
CN109311828A (en) 2019-02-05
EA036243B1 (en) 2020-10-16
JP6941630B2 (en) 2021-09-29
HRP20201524T1 (en) 2021-03-05
PT3468957T (en) 2020-09-24
UA123790C2 (en) 2021-06-02
EP3468957A1 (en) 2019-04-17
TW201803858A (en) 2018-02-01
TWI746572B (en) 2021-11-21
EP3468957B1 (en) 2020-08-26
BR112018074983A2 (en) 2019-03-12
JP2019522645A (en) 2019-08-15
MD3468957T2 (en) 2020-11-30
AU2017283768B2 (en) 2019-05-23
PH12018502523A1 (en) 2019-10-14
US10071973B2 (en) 2018-09-11
IL263299A (en) 2018-12-31
SI3468957T1 (en) 2020-11-30
KR20190018637A (en) 2019-02-25
ES2820502T3 (en) 2021-04-21
DK3468957T3 (en) 2020-09-14
MA45250B1 (en) 2020-09-30
PL3468957T3 (en) 2021-01-25
WO2017216705A1 (en) 2017-12-21
US20170355684A1 (en) 2017-12-14
ZA201807680B (en) 2019-08-28
CA3026356A1 (en) 2017-12-21
CL2018003559A1 (en) 2019-01-18

Similar Documents

Publication Publication Date Title
SG11201811414TA (en) Heterocyclic compounds as immunomodulators
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201408791TA (en) Dihydropyrimidine compounds and their application in pharmaceuticals
SG11201808708RA (en) Heterocyclic amides useful as protein modulators
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201809559UA (en) Substituted pyridines as inhibitors of dnmt1
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201901658PA (en) Beta-lactamase inhibitor compounds
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201909429VA (en) 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections
SG11201901374WA (en) Antibiotic compounds
SG11201908660RA (en) N-substituted indole derivatives
SG11201908114UA (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
SG11201407402TA (en) Carbazole-containing sulfonamides as cryptochrome modulators
SG11201908729UA (en) Phenyl derivatives as pge2 receptor modulators
SG11201806480UA (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
SG11201901249YA (en) Aza-indazole compounds for use in tendon and/or ligament injuries
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201903327PA (en) Crystalline forms of eravacycline
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders